Press Release:
Total Artificial Heart Patient Who Received Dual Transplant
Celebrates 1st Christmas at Home with 2-Year-Old Son & Fiancée
46-Year-Old Father is 2nd Total Artificial Heart Patient in the World
to Receive Heart & Kidney Transplant

December 2009: Total Artificial Heart recipient Chuck Besen and his fiancée Jennifer Hokanson celebrate their first Christmas at home with their 2-year-old son Dylan.
TUCSON, Ariz. – Dec. 15, 2009 – Last December, there were only two things 46-year-old Chuck Besen wanted for Christmas… a matching donor heart and kidney. This year, thanks to the SynCardia temporary CardioWest™ Total Artificial Heart and the dual transplant he received at University Medical Center (UMC) in March, Besen will celebrate his first Christmas at home with his 2-year-old son Dylan and his fiancée Jennifer Hokanson.
“Today, I just thank God I’m alive,” said Besen. “The Total Artificial Heart not only saved my life, but allowed me to get strong enough to undergo my dual transplant.”
“It’s incredible how our whole life has changed,” said Hokanson. “This whole journey has been an integral part of Dylan’s life. He was only 8 months old when it all began. If it weren’t for family, we don’t know what we would have done. We’re very lucky to have each other.”

May 2008: Chuck Besen with his 4-month-old son Dylan
In October 2008, Besen checked into a Las Vegas hospital to undergo a routine aortic valve replacement. However, after the valve was replaced, his heart wouldn’t start beating again.
Besen was flown by air ambulance to UMC in Tucson, AZ. To save his life, Besen was implanted with the Total Artificial Heart in the next day.
“With the Total Artificial Heart, my organs started coming back,” said Besen. “My liver came back first. All my organs eventually came back except for my kidneys. The doctors put me on the waiting list for both a heart and kidney transplant.”

January 2009: Total Artificial Heart patient Chuck Besen and his fiancée Jennifer Hokanson celebrate their son Dylan’s first birthday in the hospital during the Super Bowl.
After a little more than a month on the waiting list, on March 27, 2009, Besen became the second Total Artificial Heart patient in the world to receive a dual heart and kidney transplant. Besen was discharged from the hospital on April 10, 2009. He and his family were able to move back home to Las Vegas on Aug. 1, 2009.
“Without the Total Artificial Heart, there is no doubt in my mind that we wouldn’t be sitting here sharing our story today,” said Hokanson.
###
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660
SynCardia temporary CardioWest™ Total Artificial Heart.


